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Abstract: The common causes of hyperadrenocorticism (HAC) are pituitary ACTH-secreting 
corticotroph tumours, known as pituitary-dependent hyperadrenocorticism, and cortisol-secreting 
adrenal tumours. The only licensed medical treatment in the UK is trilostane. This treatment improves 
the clinical signs of HAC in the majority of cats and dogs. There are a number of alternative treatment 
options that are available for use in non-responders or as first-line treatment instead of trilostane. After 
a diagnosis of HAC is made, each option should be discussed with clients. This article discusses 
medical, surgical and radiotherapy options that should be considered to create an individualised 
treatment plan for each patient and owner.  
The common causes of hyperadrenocorticism (HAC) are pituitary ACTH-secreting corticotroph 
tumours, known as pituitary-dependent hyperadrenocorticism (PDH), and cortisol-secreting adrenal 
tumours (ATs) which can either be adenomas or carcinomas. There are rare re- ports of dogs having 
ectopic ACTH syndrome caused by non-pi- tuitary ACTH-secreting tumours, and food-dependent 
HAC. The common clinical signs of hyperadrenocorticism (HAC) are poly- dipsia, polyuria, polyphagia 
and panting (Behrend et al, 2013). The American College of Veterinary Internal Medicine has published 
a consensus statement on the diagnosis of HAC in dogs, and there are many excellent reviews on this 
topic (Kooistra and Galac, 2010; Melian et al, 2010; Behrend et al, 2013; Behrend, 2015).  
Pituitary tumours are the cause of HAC in 75 to 85% of canine and feline HAC cases, and it is most 
commonly caused by an adeno- ma (Hoenig, 2002; Kooistra and Galac, 2010; Valentin et al, 2013). 
Pituitary tumours can be categorised in several ways, for instance micro- or macro-, functional or non-
functional and adenoma or carcino- ma. Macroadenomas often protrude out of the bony indentation that 
houses the pituitary at the base of the brain, the sella turcica, and are >10 mm, although classification 
based on a cut-off size of 10 mm has questionable utility in veterinary medicine (Meij et al, 2002; Wood 
et al, 2007). In addition to the common clinical signs of HAC, pituitary macroadenomas may cause 
central blindness or neurological disease, secondary to a space-occupying lesion effect (Goossens et al, 
1998; Wood et al, 2007). There are a number of different treatment options for PDH and ATs, and 
clinicians should individualise treatment ac- cording the specific presentation of the animal and 
preference of the owner. The age of the animal at diagnosis and long-term costs are some of the factors 
that should be considered. 
 
Medical Management 
Trilostane (Vetoryl, Dechra, Shrewsbury, UK) has been shown to be extremely useful in the 
management of PDH. One of mecha- nism of actions is the inhibition of 3-β hydroxysteroid 
dehydrogenase, an essential enzyme during steroidogenesis in the adrenal gland. Trilostane has been 
shown to impressively improve the clinical signs of HAC in 86% and between 67 to 100% of cats and 
dogs, respectively (Ramsey, 2010; Mellett Keith et al, 2013). Trilostane is sold as 10 mg, 30 mg, 60 mg 
and 120 mg hard capsules, is recommended by many as a preferred treatment modality, and is the only 
licensed drug to treat canine HAC in the UK. Trilostane is rapidly absorbed from the gastrointestinal 
tract after oral administration, and bioavailability is improved when given with food. Peak serum 
concentrations of trilostane and the primary active metabolite, ketotrilostane, occur 30 to 90 minutes 
after oral administration, and peak serum cortisol reduction occurs between four to six hours after 
administration (Vetoryl datasheet, Dechra, Shrews- bury, UK). A starting dose of 2–5 mg/kg/day is 
recommended, and the addition of a 10 mg capsule to the product range has made prescription of these 
doses more practical (Ramsey, 2010). 
Patient monitoring is performed as recommended by the data- sheet, and dose alterations prescribed 
gradually to achieve control of clinical signs and biochemical control. The monitoring of trilostane-
treated hyperadrenocorticoid dogs is challenging if the supply of synthetic ACTH is restricted. Recent 
studies have investigated the use of serum cortisol and serum cortisol to endogenous plasma ACTH 
ratio to monitor patients during trilostane therapy (Cook and Bond, 2010; Burkhardt et al, 2013). Serum 
cortisol, measured two to three hours post-trilostane administration, above 28 mmol/l excluded  
excessive suppression in 97% of dogs, and four to six hour post-trilostane administration serum cortisol 
concentrations above 36 mmol/l excluded excessive cortisol suppression in 98% of dogs (Cook and 
Bond, 2010; Burkhardt et al, 2013). Three- hour post-trilostane administration serum cortisol 
concentration 
>120 mmol/l was an indicator of inadequate control, and four to six hours post-trilostane administration 
below 80 mmol/l excluded inadequate  control in 95% of dogs (Cook and Bond, 2010; Burkhardt et al, 
2013). However, the authors of the study concluded that endogenous ACTH or serum cortisol to 
endogenous ACTH concentrations did not adequately distinguish between excessively, adequately, and 
inadequately controlled dogs and should not be used instead of an ACTH stimulation test to monitor 
trilostane therapy (Burkhardt et al, 2013). One attractive alternative to measuring serum cortisol would 
be the measurement of urine cortisol or corticoid to creatinine ratios (UCCR). However, the majority 
of hyperadrenocorticoid dogs treated with trilostane for two months did not achieve normalisation of 
their UCCR, possibly because of the measurement of cortisol precursors that continue to be synthesised 
during trilostane therapy (Galac et al, 2009). Therefore, the UCCR test cannot be used as a monitoring 
tool for trilostane treatment. The authors recommend basal serum cortisol and electrolyte concentrations 
are measured if a patient becomes unwell during therapy, and medication is temporarily discontinued 
while await- ing results. The patient can be prescribed 0.2 mg/kg prednisolone and receive supportive 
care if sick enough to require hospitalisation. A lymphocyte count could be performed while awaiting 
the endocrine test results as patients are highly unlikely to have hypoadrenocorticism if their 
lymphocyte count is <0.75x10^9/l (Seth et al, 2011). The patient should restart trilostane at half the 
previ- ous dose when clinically well and basal cortisol is >28 mmol/l. A trilostane dose increase should 
be considered if a patient continues to exhibit clinical signs consistent with hyperadrenocorticism and 
basal cortisol is >28 mmol/l, but a slow and gradual dose increase should be prescribed. 
A proportion of dogs do not respond completely during once- daily trilostane therapy. Twice- or three 
times daily therapy could be prescribed on a trial basis based on the rationale that trilostane may not 
induce cortisol reduction for 24 hours. Twice-daily therapy is generally well tolerated and often 
improves the clinical signs of dogs affected by PDH and AT (Alenza et al, 2006; Feldman, 2008; Arenas 
et al, 2013). There are several disadvantages of trilostane for the management of HAC. Although HAC 
is typically a disease of the older dog, long-term use can prove expensive, especially in large dogs and 
those diagnosed at a young age. Dose adjustments and frequent blood test monitoring can add to the 
long-term financial cost for owners. Adverse drug effects are common, occurring in 10 to 40% of 
patients treated either one or twice daily. (Alenza et al, 2006; Arenas et al, 2013). Side effects are 
typically mild, and include gastrointestinal upset and lethargy, which may improve following dose 
reduction. However, rare cases of iatrogenic adrenal necrosis and subsequent hypoadrenocorticism have 
been reported. These are thought to be related to the increased endogenous ACTH levels causing 
increased adrenal blood flow, causing in turn a higher chance of adrenal haemorrhage, given the fragile 
nature of adrenal vessels. Trilostane treatment also leaves the inciting cause untouched. The possibility 
that a pituitary tumour could continue to grow, and cause secondary space-occupying disease, should 
be a consideration at the time of diagnosis. 
 
Figure 1: Adrenal gland steroid hormone biochemical pathways 
 
There is a general paucity of information regarding using trilostane to treat feline HAC.  The first report 
was in 2003, which described a good clinical response to 30 mg twice-daily trilostane therapy, and this 
dose appeared to be well tolerated (Skelly et al, 2003). Three subsequent case series report the response 
to trilostane therapy in five, nine and 15 cats (Neiger et al, 2004; Mellett Keith et al, 2013; Valentin et 
al, 2014). Therapy was typically well tolerated and associated with good long-term survival in many 
cases. However, up to 90% of feline HAC patients have concurrent diabetes mellitus, which is likely 
secondary to cortisol-induced insulin resistance (Graves, 2010). Trilostane therapy reduced insulin 
requirements  in 6/9 diabetic HAC cats in one study, and this was only a 36% reduction, while another 
study reported insulin doses were not reduced in any of the five diabetic HAC cats treated (Neiger et 
al, 2004; Mellett Keith et al, 2013). As insulin dose decrease has been considered an indicator of 
response to HAC treatment, unchanged insulin requirement suggests inadequate control of 
hypercortisolaemia, or permanent exocrine pancreatic disease (Valentin et al, 2014).  
 
 Figure 2. Use of contrast-enhanced T1-weighted MRI to aid diagnosis of a pituitary enlargement in a dog with hyperadrenocorticism; (a) 
pre-contrast enhanced T1-weighted intra-cranial MRI; (b) post-gadolinium contrast enhanced T1-weighted intra-cranial MRI. 
 
The Veterinary Medicines Regulations allows UK veterinarians to prescribe medications for use other 
than the authorised use if there are no licenced products or if the licenced product is unsuitable. 
Prescription of a non-licenced product should be considered if a patient experiences significant adverse 
drug effects or the licenced product is ineffective at controlling the disease. Veterinary surgeons should 
consider the reliability of the original diagnosis of HAC before prescription of an alternative 
medication, because nearly 90% of hyperadrenocorticoid dogs experience rapid clinical improvement 
during trilostane treatment. 
Mitotane (Lysodren, HRA Pharma UK and Ireland Limited, London, UK) is a prescription-only 
medicine licensed  for the symptomatic treatment of advanced adrenal corticol carcinoma in humans. 
The complete mechanism of action of mitotane is un- known, however it is primarily adrenolytic, by 
induction of free radicals, and inhibits 11β hydroxylase and desmolase in the adre- nal gland, thereby 
reduce steroid synthesis (Figure 1) (Veytsman et al, 2009). This drug successfully improves clinical 
signs of HAC in up to 87% of dogs and 50% of cats, but mitotane-associated side-effects occur in up to 
42% dogs, and clinical relapse following dose adjustments is common (Lorenz, 1982; Nelson et al, 
1988; Kintzer and Peterson, 1991; Schwedes, 1997). The common side- effects are gastrointestinal signs 
(vomiting, anorexia and diarrhoea) or weakness. Mitotane can be used for two different treatment 
strategies: it can be given life-long with gradual dose adjustment to effect, or for a short period of time 
for the induction of permanent hypoadrenocorticism.  Mitotane can be considered for patients who do 
not respond to, or experience adverse drug effects during, trilostane therapy, and for those with 
metastatic AT. 
Figure 3: Dorsal view of a T2-weighted intra-
cranial MRI to show the location of the optic 
chiasm and pituitary gland. Optic chiasm 
compression could be caused by a pituitary 
macroadenoma. 
 
 
 
Life-long therapy is prescribed as an initial ‘loading-phase’ typi- cally over eight days, followed by a 
‘maintenance phase’. The average maintenance weekly dose of mitotane in one study of 184 dogs was 
71 mg/kg, but relapse of clinical signs was common using this protocol, with around 50% of dogs 
experiencing clinical relapse within the first year of therapy, and the loading phase may need to be 
repeated in this scenario (Kintzer and Peterson, 1991). 
Adrenolytic protocols require giving higher doses of mitotane daily (typically doses of 50 to 100 
mg/kg/day given in three or four doses per day) for 25 consecutive days (Rijnberk and Belshaw, 1988; 
Feldman and Nelson, 2004; Clemente et al, 2007). Concurrent glucocorticoid and mineralocorticoid 
supplementation is started on day three of therapy. These ‘higher-dose’ protocols have been successful 
at achieving control of HAC-associated clinical signs, and have a median survival time of 720 days and 
three year survival fraction of 60% (den Hertog et al, 1999; Clemente et al, 2007). The potential side 
effects of these protocols, expense of treatment of hypoadrenocorticism (particularly in the USA), and 
risk of fatal consequences of poorly-treated hypoadrenocorticism, has caused some clinicians to 
discourage its use (Behrend, 2015). 
The adrenolytic protocols have a reported mortality rate of 5 to 10% within the first 25 days of therapy, 
although these figures may over-estimate the risk, as some of the patients had significant con- current 
disease at the time of diagnosis; 10 to 40% of incidence of gastrointestinal upset; and 30 to 40% 
incidence of disease relapse (den Hertog et al, 1999; Clemente et al, 2007). 
The use of mitotane in cats has been discouraged due to the feline sensitivity to chlorinated 
hydrocarbons and reports of seri- ous side-effects and poor response to treatment (Duesberg and 
Peterson, 1997; Nelson et al, 1988). There are reports of mitotane therapy achieving clinical control of 
feline HAC, however trilostane appears to be a more advantageous medical management option in cats 
(Schwedes, 1997). 
Trilostane versus mitotane studies have been reported.  Possibly the most applicable study to the UK 
veterinary surgeon is the study by Barker et al (2005), which reported median survival times of 662 
days and 708 days for trilostane treated and life-long mitotane therapy treated PDH respectively. Twice-
daily trilostane appeared to have a more favourable outcome for the treatment of PDH compared to a 
mitotane adrenolytic protocol, having median survival times of 900 days and 720 days, respectively 
(Clemente et al, 2007). Both trilostane and mitotane have been used to treat AT and no study to date 
has reported significantly different survival times for either drug (Helm et al, 2011; Arenas et al, 2014). 
Several prognostic factors have been proposed when using trilostane or mitotane therapy. Older age 
and heavier weight are negative prognostic  factors  reported  in  several studies;  higher one hour post-
ACTH serum cortisol, weakness at presentation, hyperphosphataemia and severity of clinical signs have 
also been reported as negative prognostic indicators (Kintzer and Peterson, 1991; Barker et al, 2005; 
Clemente et al, 2007; Arenas et al, 2014; Fracassi et al, 2014). 
 
Figure 4. (a) Photograph of a dog with 
pituitary-dependent hyperadrenocorticism; (b) 
The same dog under general anaesthesia placed 
in sternal recumbency and head placed in a 
surgical head brace to maintain an elevated 
head position; (c) The soft palate has been 
incised and retracted. The pituitary fossa has 
been exposed after burring the basisphenoid 
and presphenoid bones; (d) The soft palate has 
been closed using absorbable suture material. 
 
 
 
Figure 5. (a) Photograph of a cat with a 
diagnosis of pituitary-dependent 
hyperadrenocorticism; (b) Contrast enhanced 
computed tomography of the same cat showing 
pituitary enlargement; (c) Photomicograph 
showing haematoxylin and eosin staining of the 
pituitary tissue collected during the 
hypophysectomy surgery of the same cat. The 
cells are polygonal and exhibit the eosinophilic 
cytoplasm that is typical of corticotropes. 
 
 
 
 
 
There are a small number of studies reporting use of alternative drugs to manage HAC. Ketoconazole 
is likely to have several cortisol synthesis-inhibiting mechanisms of action, including general inhibition 
of P450 enzymes and 11β hydroxylase (Loose et al, 1983; Loli et al, 1986). However, its efficacy is 
underwhelming, especially in light of better medical options being available, despite some reports 
suggesting it to be relatively effective, with improvement of HAC-associated clinical signs in 43 of 48 
dogs and survival times comparable to mitotane and trilostane (median survival 810 vs 622 to 852 days, 
respectively) (Barker et al, 2005; Lien and Huang, 2008; Fracassi et al, 2014). Idiosyncratic 
ketoconazole-induced hepato- and other toxicity appear to be rare, but therapy is commonly associated 
with gastrointestinal upset (Lien and Huang, 2008; Mayer et al, 2008). 
 
Figure 6. (a) Ultrasound image of an enlarged adrenal 
gland. The gland has the characteristic ‘peanut’ shape but 
is enlarged at the cranial aspect; (b) A sagittal image of 
contrast-enhanced abdominal computed tomography 
identifying an enlarged adrenal gland; (c) A dorsal image 
of contrast-enhanced abdominal computed tomography. 
This is the same adrenal gland as in 4b, showing the 
relationship of the adrenal gland to the kidneys and caudal 
vena cava. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metyrapone inhibits the conversion of 11-deoxycortisol to cortisol, and successfully improved HAC 
clinical signs prior to bilateral adrenalectomy in two cats, but reports in dogs are lacking (Daley et al, 
1993; Moore et al, 2000). In summary, trilostane is the medical management option of choice for the 
UK veterinarian, and mitotane is an appropriate second line therapy. Other medical management 
options are of- ten either less effective or more frequently associated with detrimental side-effects. 
Surgical Management 
Hypophysectomy 
Hypophysectomy (surgical extirpation of the hypophysis/pitui- tary gland) is the only curative 
procedure for PDH. Around 75% of patients achieve long-term cure, but the remainder of patients 
experience disease recurrence or residual disease post-surgery (Hanson et al, 2005). Surgical debulking 
of larger pituitary tu- mours can improve or resolve neurological deficits caused by compression of the 
adjacent brain (Figures 2 and 3 reveal the location of the pituitary gland and relationship to the adjacent 
brain and optic nerves). This treatment option is available in the UK; it should be performed by an 
experienced surgeon in a facility capable of providing the intensive intra- and post-operative care 
required by these patients. Although a financial investment is required up front, subsequent medical 
management (hormonal replacement) over the long term is comparatively less expensive. Both factors 
are of relevance when considering younger animals diagnosed with hyperadrenocorticism.  
Additionally, there is a reasonable chance (approximately 20%) that without surgery the pituitary 
tumour will grow large enough to cause clinical signs and shortened life span (Kipperman et al, 1992; 
Bertoy et al, 1996; Ihle, 1997; Kent et al, 2007). 
Hypophysectomy is by no means a new procedure: the first ca- nine hypophysectomy was performed 
in 1886, and later refined by Aschner in 1912. Since these early reports, there have been sev- eral 
techniques described, including the transbuccal approach (Es- sex and Astrabadi, 1953), transoral 
approach following mandibular symphysiotomy (Henry and Hulse, 1982), and ventral paramedian 
approach between the larynx and mandibular ramus (Axlund et al, 2005). These techniques have been 
largely superseded by the transoral approach described by Meij et al (1997; 2001). The patient is 
positioned in sternal recumbency and the head elevated with mouth open. The skull-base is accessed by 
a soft palate incision and the bone ventral to the hypophyseal fossa is removed using a rotating burr 
(Meij et al, 1998). The approach is guided by referencing bony landmarks and reconstructions of pre-
operative computed tomogra- phy images. When the pituitary gland is exposed, the dura mater is incised 
and the pituitary gland extirpated using fine surgical tools. The skull defect is closed using either bone 
wax or collagen sponge, and the soft palate is closed using absorbable suture material in two layers 
(Figure 4). Medical care of the patient during the intra- and post-operative period centres on glycaemic 
and free-water control, initially cortisol and later also thyroxine supplementation. A two-week course 
of broad-spectrum bacteriocidal antibiotics is prescribed, because the surgery is performed transorally. 
Cortisol and thyroxine supplementation are life-long and titrated to effect. The hypothalamus 
synthesises vasopressin, which is normally transported to the posterior pituitary via the hypothalamic-
neurohypophyseal tract. Desmopressin (DDAVP) is prescribed to manage free-water control but, 
depending on the exact location of the pituitary stalk excision, remaining neurones in the hypothalamic-
neurohypophyseal tract may be able to release vasopressin. Around 80% of patients can be weaned off 
desmopressin over the weeks to months following surgery, however 20% develop permanent central 
diabetes insipidus and require life-long desmopressin therapy (Hanson et al, 2005). Insulin therapy is 
titrated to effect and can often be reduced or discontinued as hypercortisolaemia-induced insulin-
resistance resolves, if patients are diabetic at the time of presentation. 
The acute surgical mortality rate of humans who had Cush- ing’s disease and were treated by 
transphenoidal adenomectomy was 0 to 1.9%; remission rates were between 69 to 98% and were 
associated with tumour size and invasiveness (Kelly, 2007). Post- operative basal cortisol was a 
predictor of disease remission in this review. A report of 150 canine hypophysectomy surgeries for the 
treatment of PDH described an 8% post-operative mortality rate, with the majority of these patients 
being in the early cohort following the development of their hypophysectomy clinic (Han- son et al, 
2005). Their one-, two-, three- and four-year estimated survival rates were 84%, 76%, 72% and 68%, 
respectively. Sur- vival and disease-free fraction was lower in patients with pituitary height to brain 
area ratio >0.31, and a later study from the same group described older age, larger pituitary size and 
increased basal plasma ACTH concentration as risk factors for post-operative survival (Hanson et al, 
2007). Pre-operative urine cortisol to cre- atinine ratio was a predictor for disease recurrence, and post-
operative urine cortisol to creatinine ratio measured six to 10 weeks after surgery was a predictor for 
disease remission and survival. 
Feline hypophysectomy has been described in two case series, and the techniques used are similar to 
canine hypophysectomy (Figure 5). In the first, hypophysectomy was performed on seven 
hyperadrenocorticoid cats: two died within two weeks of surgery, and the remaining five achieved 
disease remission (Meij et al, 2001). A more recent abstract reported the treatment of twelve cats with 
hypersomatotropism and diabetes mellitus by hypophysectomy: two cats died perioperatively; of the 
surviving ten cats, seven went into complete diabetic remission, and three into par- tial remission 
(Kenny et al, 2015). 
Keratoconjunctivitis sicca (KCS) and persistent diabetes insipidus can occur after canine and feline 
hypophysectomy surgery. KCS affects a third of dogs post-operatively and although the majority 
completely recover, 20% of these dogs have persistently low tear production (Hanson et al, 2005). 
Hormone supplementation and monitoring of thyroxine is needed, since pituitary adenomectomy 
without total hypophysectomy is rarely possible. 
In summary, hypophysectomy provides a surgical alternative to medical palliation of PDH. Around 
75% of treated patients achieve disease cure without recurrence.  Life-long post-operative hormone 
supplementation is required and should be dis- cussed with owners considering this option. 
Adrenalectomy 
Bilateral adrenalectomy (BA) is the treatment of choice for bi- lateral AT. BA is more widely available 
than is hypophysectomy, and should be considered as a possible option for the treatment of PDH.  There 
are cases of ectopic ACTH production causing HAC in humans and a single case report exists of this 
disease in dogs; BA or medical management are appropriate in these cases if the primary tumour cannot 
be found or excised (Galac et al, Naan et al, 2013; Andrade et al, 2014). Patients will need life-long 
glucocorticoid and mineralocorticoid supplementation, and to be monitored in a similar manner to a 
patient with naturally occur- ring hypoadrenocorticism. As hypoadrenocorticism is more easily 
managed than hyperadrenocorticism, this remains an attractive alternative. 
A recent systemic review of BA for human AT revealed low surgical mortality (3%) and a good rate of 
resolution of clinical signs, but 43% of patients died due to thromboembolic disease (such  as  stroke  
or myocardial infarction),  progressive disease or other cause within 12 months following surgery 
(Ritzel et al, 
2013). A case series of eight cats that underwent BA for PDH has been described (Duesberg et al, 1995). 
Three of the eight cats died within three weeks of surgery from complications that could have been 
attributed to HAC induced disease and surgical com- plications. The clinical signs of the remaining five 
cats resolved by four months post-surgery, but some cats continued to require insulin therapy. There 
are case reports of bilateral adrenalectomy in dogs, but to the authors’ knowledge a large case-series 
has not been reported (Anderson et al, 2001; Hanson et al, 2007; Lang et al, 2011). 
Unilateral  adrenalectomy  is  the   treatment   of  choice  in patients  with AT, and  may be  followed 
by chemotherapy  in patients  with metastatic  disease (Figure 6 reveals the  adrenal enlargement).   
Table 1 summarises   the   findings of studies reporting case series of adrenalectomy in patients having 
AT. There are a number of different prognostic factors and survival times reported, and it should be 
noted that different surgical techniques, surgical expertise and post-operative care protocols will have 
influenced outcomes. There are no large case series of unilateral adrenalectomy for the treatment of 
feline AT, though a recent case series of 10 cats that underwent adrenalectomy for adrenal-dependent 
hyperaldosteronism revealed good post- operative recovery. Two of these 10 cats were euthanized due 
to consequences of surgery, and the remaining eight cats had good long-term survival (Lo et al, 2014). 
Although these cats will have a different metabolic derangement profile to cats having AT, this study 
suggests that it is possible to perform unilateral adrenalectomy safely in this species. 
In summary, adrenalectomy is the treatment of choice for AT. Patients undergoing bilateral 
adrenalectomy will require life-long management of hypoadrenocorticism. 
 
Radiotherapy 
Radiotherapy is considered an effective second line therapy for human PDH. Radiotherapy is prescribed 
for human patients un- suitable for hypophysectomy, or for those who experience disease persistence   
following hypophysectomy.  Radiotherapy improves survival in patients with pituitary masses, and the 
Table 1. Summaries of studies of adrenalectomy in dogs  with  cortisol-secreting adrenal tumours 
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Procedure/ disease Survival Complications  (number of patients) Prognostic  factors 
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Scavelli et 
al, 1986 
25 dogs All unilateral; 24 ventral 
midline, 1 paracostal, 
11 adenomas,  14 
carcinomas 
Adenoma: 3 survive > 
24 months; carcinoma: 
2 survive > 24 months 
12  1 7 1  1 Negative: possible AT 
carcinoma 
van Sluijs et 
al, 1995 
36 dogs 33 unilateral and 3 
bilateral 
40% probability of 
survival at 1 200 days 
10  3  1  6  
Anderson 
et al, 2001 
21 dogs 18 unilateral and 3 
bilateral; 4 
adenomas and 20 
carcinomas 
Adenoma MST not 
reached; if carcinoma 
patient survived first 14 
days, survival time 992 
days 
5  1 1 1 1 1 None 
Kyles et al, 
2003 
40 dogs 37 unilateral and 3 
bilateral 28 AT, 11 pheo, 
1 no diagnosis 
MST not reached for 
adrenalectomy 
alone; MST c. 6–8 
months 
for adrenalectomy 
and thrombectomy 
9 4 1 8 1 3 5  
Schwartz et 
al, 2008 
41 dogs Unilateral 
adrenalectomy; 19 
carcinoma 14 
adenoma 
MST carcinoma was 230 
days; MST adenoma 
687.5 days 
4 2 3  5  10 Negative: pre-operative 
hypokalaemia, 
azotaemia, kidney disease 
Lang et al, 
2011 
60 dogs 59 unilateral and 1 
bilateral; 15 
adenoma, 
26 carcinoma, 6 
hyperplasia 
If survive peri-operative 
period: 492 days 
7   21  7  Negative: acute adrenal 
haemorrhage; each 1 
mm increase in tumour 
size increased 
perioperative mortality by 
7.9% Massari et 
al, 2011 
52 dogs 25 adenomas,  18 
carcinomas, 7 pheo, 1 
other 
All-dog survival was 953 
days 
 1 1 4   2 Negative: tumour size >5, 
metastatic disease, vein 
thrombosis 
Barrera et 
al, 2013 
86 dogs 14 adenoma  and 
45 carcinoma, 27 
pheo 
All adenoma  patients 
survived; MST 
carcinoma 48 months; 
MST pheo not reached 
22 53 8 31 6 31 12 Negative: presence of 
extensive vena cava 
thrombus, but not 
tumour type 
Mayhew et 
al, 2014 
48 dogs 19 adenoma  and 
27 carcinoma 
Short-term follow-up 
only 
2  1 6   1  
AT = Adrenal tumour; CVR = Cardiovascular/respiratory; GIT = gastro-intestinal; MST = median survival time; op = operation; 
pheo = pheochromocytoma. 
response to radiotherapy and survival following treatment is negatively correlated with the ratio of 
tumour size to brain height (Theon et al, 1998; Kent et al, 2007). 
Fractionated external beam radiotherapy has been used to treat canine pituitary macroadenomas since 
1985. The first report of radiotherapy improving the neurological disease caused by a PDH 
macrotumour was in 1990 (Dow et al, 1990). Dogs received 10 fractions of 4 Gy (40 Gy total dose) 
over 22 days. Neurological status improved within three months and pituitary tumour volume reduced 
by 50% every six months for at least one year. Side effects were regional hair depigmentation, reduced 
hearing or deafness, keratoconjunctivitis sicca, and temporary vestibular syndrome; one dog started to 
seizure 17 months later and another developed unilateral trigeminal neuropathy nearly 30 months later. 
However, biochemical control of PDH following radiotherapy has been poor, and continued medical 
management has been necessary (Goossens et al, 1998; Theon et al, 1998). Fractionated radiotherapy 
can improve the diabetic control of cats with PDH, but, as in dogs, does not lead to normalisation of 
cortisol secretion (Mayer et al, 2006). 
 
Stereotactic radiosurgery, performed by delivering a single dose of radiotherapy to a defined target area, 
has been performed in dogs with pituitary neoplasia, but the ability of this treatment to control canine 
PDH is not yet known (Mariani et al, 2013). Stereotactic radiosurgery for PDH has been reported in 
two cats. One cat was receiving concurrent trilostane and experienced clinical improvement within nine 
months after radiosurgery; the other cat was euthanised two months after treatment due to suspected 
abdominal neoplasia. Larger studies are needed to understand the role that radiosurgery could have in 
the management of PDH. 
In summary, radiotherapy can play a limited role in the man- agement of hyperadrenocorticism. It 
appears most useful to shrink the pituitary tumour, but seems less useful to achieve hormonal 
normalisation. 
 
Malignant neoplasms 
Pituitary carcinomas are rare; adenomas are most commonly en- countered. They are defined by 
metastatic behaviour rather than by invasive or histopathology characteristics in human endocrinology 
(Kaltsas et al, 2005). The treatment of humans affected by pituitary carcinomas is mainly palliative. 
The incidence of this type of tumour in veterinary species in not known, nor is the most appro- priate 
treatment protocol. Treatment would likely involve a combi- nation of surgery, radiotherapy and 
medical treatments including cytotoxic chemotherapy, in an attempt to improve quality of life. 
However, euthanasia should be considered if the patient’s quality of life does not improve in response 
to therapy. 
Adrenal tumour invasion and/or metastatic disease are used to differentiate adrenal cortical adenomas 
from carcinoma in human pathology, and an adrenal mass ≥2 cm is likely to be malignant in canine 
medicine (Cook et al, 2014). In the absence of these fea- tures, the Weiss system, which assesses nine 
different histopatho- logical features, is commonly used in human pathology to assess adrenal tumour 
malignancy (Weiss, 1984). Adrenal carcinomas should be excised if possible, because this is positively 
correlated with survival in humans (Fulmer, 2007). Metastatic disease is a negative prognostic factor, 
and adjuvant treatment with mitotane or mitotane plus cytotoxic chemotherapy may improve survival 
further (Helm et al, 2011). 
The opinion of the authors is that veterinary patients are probably best monitored for the development 
of metastatic disease and receive treatment if/when this disease occurs. Cytotoxic chemo- therapy 
typically has disappointing success as the primary and sole therapy for adrenal cortical neoplasia, and 
the benefits of adjuvant chemotherapy without metastatic disease do not outweigh possible side-effects. 
In summary, surgical excision of malignant AT is an appropriate treatment option and can prove very 
satisfactory if performed at a time prior to metastatic disease. Malignant PDH is fortunately rare. 
Conclusion 
Trilostane is a good treatment option for many patients suffering from hyperadrenocorticism, but there 
is more to consider than trilostane treatment after a diagnosis of HAC has been made. Clinicians should 
encourage owners to invest in differentiating PDH from AT. Additionally, the full range of treatment 
options should be discussed, so that therapy is tailored to the individual patient and owner rather than 
the recommendation of a single therapy for all patients. 
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